National Leader Children's Hospital Colorado To Adopt Milestone Scientific's The Wand® STA® As Exclusive Instrument For Pediatric Dental Injections

Provides children "the most comfortable, safest and stress-free experience"

Livingston, NJ (Marketwired) - Milestone Scientific Inc . (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Children's Hospital Colorado, one of the top children's hospitals in the nation, will exclusively use The Wand® STA® for all pediatric dental injections beginning in January 2018.

The Wand® STA® is the market-leading computer-controlled local anesthesia system, with over 60 million injections performed worldwide. The Wand® STA performs both traditional and newer dental anesthesia injections in a more effective and comfortable way for both the patient and the provider. The instrument utilizes patented technologies like computer-regulated flow rates, Dynamic Pressure Sensing (DPS®), and a uniquely ergonomic hand-piece to enable significant improvements over the traditional dental syringe and needle, which has remained virtually unchanged for over 160 years.

Dr. Mark Hochman, D.D.S, Director of Clinical Affairs for Milestone Scientific and a world authority on computerized injection technology, commented, "We are honored that Children's Hospital Colorado has adopted the The Wand® STA® exclusively for its pediatric dentistry patients. Coming on the heels of a similar announcement from the Children's Hospital of Pittsburgh, this is further validation that our technology offers the most comfortable, painless, safest, and stress-free experience. We commend the Children's Hospital Colorado on their commitment to providing pediatric patients the best-in-class experience."

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website:www.milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.